10-1074 vs UVAX-1107
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV envelope · full HIV pipeline
10-1074
Developed by Gilead Sciences under a licence from The Rockefeller University
NCT03707977 · Phase 1/2 · completed
This was a small, nonrandomized, open-label study without a comparator arm, enrolling 30 children overall and evaluating viral-load and safety outcomes descriptively. All participants received 10-1074 together with a second antibody, VRC01LS, so the results describe the dual-antibody regimen, not 10-1074 alone. The primary viral outcomes were reported as 11 of 25 below 400 copies/mL and 10 of 25 below 40 copies/mL at Week 24, but there was no controlled comparison or formal significance test.
Reported efficacy
Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant); Severity of Treatment-associated AEs (Number of Participants With Grade 3 or Higher Related AEs) (Measured until 30 days after study completion for each participant); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 400 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2); Proportion of Children Who Maintain HIV-1 Plasma RNA Less Than 40 Copies/mL, After Initiating VRC01LS and 10-1074 Infusions and Stopping ART (Measured through Week 24 of Step 2): Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] (Measured until 30 days after study completion for each participant): Group PK-A: ART + VRC01LS 4 Participants | Group PK-B: ART + 10-1074 1 Participants | Steps 1-3 Participants (ART + 10-1074 + VRC01LS) 19 Participants (not_applicable)
Result source: NCT03707977
UVAX-1107
Developed by Uvax Bio
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | 10-1074 | UVAX-1107 |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not reported |
| CD4 count, change (week 48) | —Not reported | —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- 10-1074
- —Not reported
- UVAX-1107
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- 10-1074
- —Not reported
- UVAX-1107
- —Not reported
CD4 count, change (week 48)
- 10-1074
- —Not reported
- UVAX-1107
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
UVAX-1107: no structured comparison results are available for HIV.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. 10-1074: 3 of 4 rows · UVAX-1107: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | 10-1074 |
|---|---|
| Dropout rate | 0%Group PK-B: ART + 10-1074 NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 show 3 more results—PK Step (ART + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 —Step 1 (ART + VRC01LS + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 —Step 2 (VRC01LS + 10-1074 Only) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 |
| Discontinued due to AEs | —Group PK-B: ART + 10-1074 NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 show 3 more results—PK Step (ART + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 —Step 1 (ART + VRC01LS + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 —Step 2 (VRC01LS + 10-1074 Only) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 |
| Serious AEs | —Group PK-B: ART + 10-1074 NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 show 3 more results0%PK Step (ART + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 0%Step 1 (ART + VRC01LS + 10-1074) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 4%Step 2 (VRC01LS + 10-1074 Only) NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 |
| Most frequent reported AEs | show 2 more resultsneutrophil count decreased 35.7% haemoglobin decreased 28.6% cough 25% NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 cough 44% upper respiratory tract infection 32% haemoglobin decreased 28% NCT03707977 · Phase 1/2 · combination · HIV · phase 1/2 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 10-1074's landscape · UVAX-1107's landscape